Cite
HARVARD Citation
Grogan, B. et al. (n.d.). 696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo. Journal for immunotherapy of cancer. pp. A418-A419. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Grogan, B. et al. (n.d.). 696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo. Journal for immunotherapy of cancer. pp. A418-A419. [Online].